The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine
Go back to The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 32.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.20 | 52 Week High | $66.55 | |||
| Open | $32.20 | 52 Week Low | $37.82 | |||
| Day High | $32.20 | P/E | N/A | |||
| Day Low | $32.20 | EPS | $0.00 | |||
| Volume | 14,762 | |||||
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 32.20 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.20 | 52 Week High | $66.55 | |||
| Open | $32.20 | 52 Week Low | $37.82 | |||
| Day High | $32.20 | P/E | N/A | |||
| Day Low | $32.20 | EPS | $0.00 | |||
| Volume | 14,762 | |||||
